Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Spero Therapeutics' Shares Plunge As FDA Issued Refusal Letter For Urinary Tract Infection Candidate

The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) in response to Spero Therapeutics ‘ (NASDAQ:SPRO) New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for the treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis.

The New Drug Application (NDA) was supported by the clinical data readout from the Phase 3 study investigating tebipenem HBr.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.